IPO registrations (S-1, F-1) · Registrants
Aceragen, Inc.
- SEC CIK
- 861838 · filings on EDGAR ↗
- Name on the registration
- IDERA PHARMACEUTICALS, INC.
- Former names
- IDERA PHARMACEUTICALS, INC. (2005–2023); HYBRIDON INC (1996–2005)
- Registration
- Form S-1, first filed 1998-12-23, last 2013-05-01; 3 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2013-05-02; declared effective 2006-08-09
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 505 EAGLEVIEW BOULEVARD, SUITE 212, Exton, PA 19341
- EIN
- 04-3072298
- EDGAR entity type
- operating
- Insiders and CEO pay
- Aceragen, Inc. on the corporate pages
Offering terms
- Final price
- $0.50 per share (424B4 filed 2013-05-02)
- Shares sold
- 17,500,000
- Gross proceeds
- $8,750,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol IDRA
- Lead underwriters
- Piper Sandler
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form 5500 plan sponsor: IDERA PHARMACEUTICALS, INC. EXACT (EIN (EXACT))
- SEC filer: Aceragen, Inc. EXACT (CIK (EXACT))
- Person page: C Keith Hartley Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Mark J Casey Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
Filings 29
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 1998-12-23 | S-1 | S-1 (registration) | HYBRIDON INC | 0000922423-98-001428 ↗ |
| 1999-07-07 | S-1/A | S-1/A (amendment) | HYBRIDON INC | 0000922423-99-000859 ↗ |
| 2000-02-15 | S-1/A | S-1/A (amendment) | HYBRIDON INC | 0000922423-00-000370 ↗ |
| 2000-12-29 | S-1/A | S-1/A (amendment) | HYBRIDON INC | 0000950135-00-005579 ↗ |
| 2001-02-05 | S-1/A | S-1/A (amendment) | HYBRIDON INC | 0000950135-01-000268 ↗ |
| 2006-08-09 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-06-001139 ↗ |
| 2006-08-14 | S-1 | S-1 (registration) | IDERA PHARMACEUTICALS, INC. | 0000950135-06-005044 ↗ |
| 2006-10-19 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-06-001965 ↗ |
| 2007-01-16 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-07-000184 ↗ |
| 2007-02-08 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-07-000523 ↗ |
| 2007-05-08 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-07-001808 ↗ |
| 2007-08-31 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-07-003512 ↗ |
| 2010-09-03 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-10-002638 ↗ |
| 2011-12-21 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-11-003602 ↗ |
| 2013-01-17 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-13-000212 ↗ |
| 2013-02-08 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-13-000440 ↗ |
| 2013-03-11 | S-1 | S-1 (registration) | IDERA PHARMACEUTICALS, INC. | 0001193125-13-100015 ↗ |
| 2013-04-23 | S-1/A | S-1/A (amendment) | IDERA PHARMACEUTICALS, INC. | 0001193125-13-166154 ↗ |
| 2013-05-01 | S-1/A | S-1/A (amendment) | IDERA PHARMACEUTICALS, INC. | 0001193125-13-190099 ↗ |
| 2013-05-01 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-13-001341 ↗ |
| 2013-05-02 | 424B4 | 424B4 (final prospectus) | IDERA PHARMACEUTICALS, INC. | 0001193125-13-196487 ↗ |
| 2013-07-10 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-13-002045 ↗ |
| 2013-08-27 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-13-002521 ↗ |
| 2013-08-28 | 424B4 | 424B4 (final prospectus) | IDERA PHARMACEUTICALS, INC. | 0001193125-13-350307 ↗ |
| 2013-09-18 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-13-002708 ↗ |
| 2013-09-30 | 424B4 | 424B4 (final prospectus) | IDERA PHARMACEUTICALS, INC. | 0001193125-13-384811 ↗ |
| 2013-11-15 | 424B4 | 424B4 (final prospectus) | IDERA PHARMACEUTICALS, INC. | 0001193125-13-443926 ↗ |
| 2013-12-06 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-13-003468 ↗ |
| 2014-05-22 | EFFECT | EFFECT (declared effective) | IDERA PHARMACEUTICALS, INC. | 9999999995-14-001575 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2013-05-01 | S-1/A | registration statement | - | - | Nasdaq IDRA | 1 | primary document; cover names 1 | document ↗ | ||
| 2013-05-02 | 424B4 | final prospectus | $0.50 | 17,500,000 | $8,750,000 | Nasdaq IDRA | 1 | primary document; price sentence, shares headline, proceeds computed, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Alison Taunton-Rigby | Director | 13 | 2006–2009 | ||
| HARTLEY C KEITH | Director | 20 | 2006–2013 | person page Fuzzy | |
| REARDON WILLIAM S | Director | 34 | 2006–2018 | ||
| WYNGAARDEN JAMES B | Director | 26 | 2006–2011 | ||
| ZAMECNIK PAUL C | Director; Other | 21 | 2006–2008 | ||
| ZEIN YOUSSEF EL | Director; Director,TenPercentOwner; TenPercentOwner | 91 | 2006–2023 | ||
| AGRAWAL SUDHIR | Director,Officer | CEO & CSO; CEO & President; CEO, President & CSO; Chairman, CEO & President; President of Research | 26 | 2006–2017 | |
| ANDERSEN ROBERT G | Officer | CFO & VP Oper. and Planning | 5 | 2006–2007 | |
| 14159 capital (GP), LLC | TenPercentOwner | 21 | 2006–2008 | ||
| Baker Biotech Capital (GP), LLC | TenPercentOwner | 20 | 2006–2008 | ||
| Baker Biotech Capital II (GP), LLC | TenPercentOwner | 3 | 2006 | ||
| Baker Biotech Capital III (GP), LLC | TenPercentOwner | 24 | 2006–2008 | ||
| Baker Biotech Capital III (Z) (GP), LLC | TenPercentOwner | 3 | 2006 | ||
| Baker Biotech Capital II (Z) (GP), LLC | TenPercentOwner | 3 | 2006 | ||
| Baker Bros. Capital (GP), LLC | TenPercentOwner | 20 | 2006–2008 | ||
| BAKER FELIX | Director; Director,TenPercentOwner; Other; TenPercentOwner | 126 | 2006–2019 | ||
| BAKER JULIAN | Director; Director,TenPercentOwner; Other; TenPercentOwner | 126 | 2006–2019 | ||
| Sullivan Timothy M | Officer | VP Development Programs | 14 | 2006–2014 | |
| Karr Robert W | Director; Director,Officer | President | 11 | 2006–2014 | |
| Bexon Alice | Officer | V.P. Clinical Development | 5 | 2007–2009 | |
| MUELLER HANS | Director | 13 | 2007–2011 | ||
| Arcudi III Louis J | Officer | Chief Financial Officer | 15 | 2007–2018 | |
| MacCoss Malcolm | Director | 11 | 2010–2014 | ||
| Arbeit Robert D. | Officer | VP Clinical Development | 7 | 2010–2013 | |
| Slater Eve Elizabeth | Director | 8 | 2010–2015 | ||
| Senator Investment Group LP | TenPercentOwner | 7 | 2010–2012 | ||
| Pillar Invest Corp | Director,TenPercentOwner; TenPercentOwner | 37 | 2011–2023 | ||
| Pillar Pharmaceuticals I LP | Director,TenPercentOwner; TenPercentOwner | 17 | 2011–2020 | ||
| Abdul-Wahab Umari | Director | 12 | 2012–2014 | ||
| Pillar Pharmaceuticals II, L.P. | Director,TenPercentOwner; TenPercentOwner | 17 | 2012–2020 | ||
| Pillar Pharmaceuticals III, L.P. | Director,TenPercentOwner; TenPercentOwner | 11 | 2013–2020 | ||
| GERAGHTY JAMES A | Director | 29 | 2013–2022 | ||
| Pillar Pharmaceuticals IV, L.P. | Director,TenPercentOwner; TenPercentOwner | 9 | 2013–2020 | ||
| BRENNER LOUIS MD | Officer | Chief Medical Officer | 3 | 2014 | |
| Goldberg Mark Alan | Director | 18 | 2014–2022 | ||
| 14159, L.P. | Director; Director,TenPercentOwner | 33 | 2014–2019 | ||
| 667, L.P. | Director; Director,TenPercentOwner | 33 | 2014–2019 | ||
| Baker Bros. Advisors (GP) LLC | Director; Director,TenPercentOwner; TenPercentOwner | 35 | 2014–2019 | ||
| BAKER BROS. ADVISORS LP | Director; Director,TenPercentOwner; TenPercentOwner | 35 | 2014–2019 | ||
| Baker Brothers Life Sciences LP | Director; Director,TenPercentOwner | 33 | 2014–2019 | ||
| Neu Kelvin | Director | 1 | 2014 | ||
| MILANO VINCENT | Director; Director,Officer | President and CEO; PRESIDENT AND CEO; President & CEO | 24 | 2014–2023 | |
| Wolf John Peter III | Officer | General Counsel | 2 | 2014 | |
| Fletcher Robert C. | Officer | Sr. VP, Bus. Dev. & Strategy | 12 | 2015–2020 | |
| Casey Mark J | Officer | Senior VP and General Counsel; Senior VP & General Counsel | 6 | 2015–2018 | person page Fuzzy |
| Horobin Joanna | Officer | Chief Medical Officer; SVP and Chief Medical Officer | 8 | 2015–2019 | |
| GOWEN MAXINE | Director | 14 | 2016–2023 | ||
| Pillar Pharmaceuticals V LP | Director,TenPercentOwner; TenPercentOwner | 4 | 2016–2020 | ||
| YINGLING JONATHAN MICHAEL | Officer | Chief Scientific Officer; SVP, Early Development; SVP of Early Development | 9 | 2017–2020 | |
| Lim Bryant David | Officer | SVP and General Counsel; SVP AND GENERAL COUNSEL; SVP & General Counsel | 19 | 2018–2023 | |
| PIEN HOWARD H | Director | 12 | 2018–2020 | ||
| Kirby John J. | Officer | Chief Financial Officer; CHIEF FINANCIAL OFFICER; VP of Finance; V.P. of Finance, PFO & PAO | 17 | 2018–2023 | |
| SCHAFER CAROL | Director | 14 | 2018–2022 | ||
| Csimma Cristina | Director | 6 | 2019–2022 | ||
| DOUGHERTY MICHAEL R | Director | 20 | 2019–2023 | ||
| Tarka Elizabeth Ann | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 6 | 2019–2021 | |
| Pillar Partners Foundation, L.P. | TenPercentOwner | 15 | 2019–2023 | ||
| Pillar Pharmaceuticals 6, L.P. | TenPercentOwner | 12 | 2019–2023 | ||
| Umari Abude | TenPercentOwner | 15 | 2019–2023 | ||
| SOLAND DANIEL B | Officer | Chief Operating Officer; CHIEF OPERATING OFFICER | 8 | 2021–2022 | |
| JORDAN ANDREW R | Officer | Chief Strategy Officer; CHIEF STRATEGY OFFICER | 5 | 2022–2023 | |
| Kraus Carl N | Officer | Chief Medical Officer; CHIEF MEDICAL OFFICER | 4 | 2022–2023 | |
| Salain Daniel | Officer | Chief Operating Officer; CHIEF OPERATING OFFICER | 4 | 2022–2023 | |
| Taylor John Clayton | Director,Officer | Chief Executive Officer; CHIEF EXECUTIVE OFFICER | 4 | 2022–2023 | |
| WOOTEN RONALD J | Director | 3 | 2022–2023 | ||
| NovaQuest Co-Investment Fund XV, L.P. | Director,Other; DirectorOther | 3 | 2022–2023 | ||
| NQ POF V GP, Ltd. | Director,Other; DirectorOther | 3 | 2022–2023 | ||
| Chopra Atul | TenPercentOwner | 4 | 2023 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | IDERA PHARMACEUTICALS, INC. | PA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| SEC filer | Aceragen, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Form 5500 plan sponsor | IDERA PHARMACEUTICALS, INC. | EIN (EXACT) | ||
| Person page | C Keith Hartley | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Mark J Casey | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), PA first:
- APOLLON INC PA
- Aevi Genomic Medicine, LLC PA
- Ocugen, Inc. PA
- Spark Therapeutics, Inc. PA
- Krystal Biotech, Inc. PA
- Cabaletta Bio, Inc. PA
- Passage BIO, Inc. PA
- Century Therapeutics, Inc. PA
- Aphton CORP PA
- GENAERA CORP PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health